GoodRx Holdings, Inc. has 6 Schedule 13D or 13G filings on record since 2025-07-03. 1 holder's latest filing reports 5% or more of class a common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Francisco Partners IV, L.P. | 32.9% | 35,023,391 | SCHEDULE 13D/A, 2026-08-26 | 2026-08-19 |
| Spectrum Equity VII, L.P. | 0% | 0 | SCHEDULE 13D/A, 2025-10-16 | 2025-10-14 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Purpose of Transaction (Item 4)
Spectrum Equity VII, L.P.
Item 4 of the Schedule 13D is hereby amended to include the following at the end thereof: On October 14, 2025, SE VII distributed 8,881,362 shares of the Issuer's Class A Common Stock pro rata to its limited partners for no consideration (the "October 2025 Distribution"). Following the October 2025 Distribution, Spectrum VII Co-Investment Fund, L.P. and Spectrum VII Investment Managers' Fund, L.P. made open market sales of an aggregate of 23,771 shares of the Issuer's Class A Common Stock for net proceeds of $95,103.02 (such sales, the "October 2025 Sales").Item 4 of the SCHEDULE 13D/A filed 2025-10-16
Francisco Partners IV, L.P.
Item 4 of the Original 13D is hereby amended to include the following at the end thereof: On August 20, 2026, Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P. converted 4,995,903 and 2,504,097 Class B Shares to Class A Shares and distributed in kind 3,596,648 and 1,142,357 Class A Shares, respectively, to their respective general partner and limited partners, and each such general partner in turn distributed such Class A Shares to its ultimate direct or indirect partners (such distributing entity the "FP Entities" and the "August 2026 Francisco Partners Distribution"), in each case, pro rata and for no consideration. In addition, on such date, the remaining 2,743,043 Class A Shares received upon such conversion were sold by the FP Entities for an aggregate consideration of $9,678,731.4997, which proceeds were distributed to their respective partners.Item 4 of the SCHEDULE 13D/A filed 2026-08-26
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-03 | Spectrum Equity VII, L.P. | 12.9% | SCHEDULE 13D/A |
| 2025-09-08 | Spectrum Equity VII, L.P. | 8.28% | SCHEDULE 13D/A |
| 2025-10-16 | Spectrum Equity VII, L.P. | 0% | SCHEDULE 13D/A |
| 2025-10-30 | The Vanguard Group | 9.33% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-08-26 | Francisco Partners IV, L.P. | 32.9% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for GoodRx Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.